Anteris Technologies Global
Anteris Technologies Global's revenue fell 29.2% to $2 million in fiscal 2025. Its operating margin was −4,908.2%, down from −2,899.4% a year earlier. Free cash flow was −$80 million. The diluted share count rose 82.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Anteris Technologies Global does
Anteris is a heart valve company. Its lead product, the DurAVR transcatheter heart valve system, is meant to treat aortic stenosis, a narrowing of the heart's aortic valve that can be life-threatening. The valve is delivered through a catheter rather than by open-heart surgery, a method called TAVR.
The company says its valve is a single piece shaped to mimic a healthy human aortic valve, in contrast to the traditional three-piece design. It is made with Anteris's ADAPT tissue technology, which treats animal tissue to resist calcium build-up. The company says its ADAPT tissue has been used in other heart procedures in many patients worldwide.
As the 10-K describes, DurAVR is still being studied in early clinical studies in the United States and Europe, and the company has a history of operating losses. It describes its lead product as one it hopes to bring to market for all kinds of aortic stenosis patients, including younger and less-active ones.
Its biggest risks, as it describes them
- It has a history of operating losses and may not become profitable.
- Unsuccessful clinical trials or procedures could badly hurt its prospects.
- It may fail to win regulatory clearance or approval for its products, or be delayed in doing so.
- Developing its pipeline of products is costly, slow and uncertain.
- Coverage and reimbursement decisions by government health programs and insurers could hurt its profits.
Income statement
Anteris Technologies Global lost money in fiscal 2025: a net loss of $94 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | 70 | 13 |
| Debt incl. finance leases | — | 0 |
| Net debt (negative means net cash) | — | −13 |
| Net debt to EBITDA | — | — |
| Debt to equity | — | — |
| Interest coverage | −1,667.5x | −1,286.2x |
| Current ratio | 4.5x | 0.7x |
| Quick ratio | 4.5x | 0.7x |
Cash flow
Projections
Project Anteris Technologies Global's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Anteris Technologies Global reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 |
|---|---|
| Piotroski F-score | — |
| Rule of 40 | −4,198.4% |
| Altman Z'' | −81.60 |
| Accruals ratio | −31.5% |
The nine F-score tests
| Test | FY25 |
|---|---|
| Net income is positive | Fail |
| Cash from operations is positive | Fail |
| Return on assets rose | — |
| Cash from operations exceeds net income | Pass |
| Debt fell relative to assets | — |
| Current ratio rose | Fail |
| Share count didn't rise | Fail |
| Gross margin rose | Pass |
| Revenue rose relative to assets | — |
| F-score | — |
Compare
Put Anteris Technologies Global side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Anteris Technologies Global | FY25 | −29.2% | −4,908.2% | −4,169.2% | — | — | — | |
| Pulse Biosciences | FY25 | — | −21,982.6% | −15,553.4% | — | — | 3 | Compare |
| IRADIMED | FY25 | 14.4% | 31.2% | 20.5% | — | — | — | Compare |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | Compare |
2 years of figures
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | 3 | 2 |
| Revenue growth | — | −29.2% |
| Gross profit | 1 | 1 |
| Research and development | 52 | 69 |
| Operating income | −78 | −94 |
| Net income | −76 | −94 |
| Diluted EPS (US$) | −3.68 | −2.55 |
| Diluted shares (millions) | 20 | 37 |
| Cash flow | ||
| Cash from operations | −61 | −78 |
| Capital expenditure | 2 | 2 |
| Free cash flow | −64 | −80 |
| Dividends paid | 0 | 0 |
| Share buybacks | 0 | 0 |
| Acquisitions | 0 | 0 |
| Stock-based compensation | 6 | 8 |
| Balance sheet at fiscal year end | ||
| Cash and short-term investments | 70 | 13 |
| Debt incl. finance leases | — | 0 |
| Total assets | 81 | 23 |
| Total liabilities | 18 | 23 |
| Shareholders' equity | 63 | −0 |
| Margins and ratios | ||
| Gross margin | 46.8% | 70.3% |
| Operating margin | −2,899.4% | −4,908.2% |
| Net margin | −2,822.5% | −4,921.3% |
| Free cash flow margin | −2,349.5% | −4,169.2% |
| Rule of 40 (growth + FCF margin) | — | −4,198.4% |
| Return on capital | — | — |
| Return on equity | — | −300.4% |
| Return on assets | — | −181.6% |
| Net debt to EBITDA | — | — |